New drug combo shows promise for rare sarcoma
NCT ID NCT04172805
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of two drugs—anlotinib (a targeted therapy) and toripalimab (an immunotherapy)—in 70 people with advanced soft-tissue sarcoma that had stopped responding to standard treatment. The goal was to see if the combo could shrink tumors or slow disease progression. Results could point to a new option for this rare cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anlotinib and toripalimab (a targeted drug and an immunotherapy drug)
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced soft-tissue sarcoma who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not be definitive. The combination may cause side effects and may not work for all sarcoma types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xing Zhang
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
- New chemo combo shows promise for rare sarcoma
- New drug cocktail shows promise for rare sarcomas
- New study tracks how cancer surgery affects Kids' walking
- Scientists launch international registry to crack the code of ultra-rare cancer EHE